Details:
Proceeds from the equity investment will be used to advance and expand MiNA’s internal pipeline of saRNA therapeutics, which is initially focused on immuno-oncology and genetic diseases.
Lead Product(s): RNA-based Medicines
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Agreement July 06, 2021